The evolving role of Alemtuzumab in management of patients with CLL
Open Access
- 20 October 2005
- journal article
- review article
- Published by Springer Nature in Leukemia
- Vol. 19 (12) , 2147-2152
- https://doi.org/10.1038/sj.leu.2403984
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administrationBlood, 2004
- Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletionsBlood, 2004
- Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)Leukemia, 2004
- Maintenance Therapy with a Monthly Injection of Alemtuzumab Prolongs Response Duration in Patients with Refractory B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (B-CLL/SLL)Leukemia & Lymphoma, 2004
- Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemiaCancer, 2003
- Phase II study of alemtuzumab in chronic lymphoproliferative disordersCancer, 2003
- Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesBlood, 2003
- Monoclonal Antibody Therapy of Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2003
- Cell Surface Antigen and Molecular Targeting in the Treatment of Hematologic MalignanciesThe International Journal of Cell Cloning, 2002
- Frequency and type of serious infections in fludarabine‐refractory B‐cell chronic lymphocytic leukemia and small lymphocytic lymphomaCancer, 2002